Joann Olsen
Psychosomatic Medicine · Skokie, ILNPI 1316160435
Payments from drug & device makers
Across 196 payments — averaging $18.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$781
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$504
- Otsuka America Pharmaceutical, Inc.$238
- Neurocrine Biosciences, Inc.$234
- Takeda Pharmaceuticals U.S.A., Inc.$222
- E.r. Squibb & Sons, L.L.C.$204
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,62999%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 62 | $781 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $504 |
| Otsuka America Pharmaceutical, Inc. | 14 | $238 |
| Neurocrine Biosciences, Inc. | 9 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $222 |
| E.r. Squibb & Sons, L.L.C. | 9 | $204 |
| Johnson & Johnson | 9 | $190 |
| Lundbeck LLC | 9 | $166 |
| Ironshore Pharmaceuticals Inc. | 6 | $123 |
| Axsome Therapeutics, Inc. | 4 | $109 |
| Neos Therapeutics, LP | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $72 |
| Shire North American Group Inc | 3 | $65 |
| Alkermes, Inc. | 3 | $63 |
| Bioxcel Therapeutics, Inc. | 1 | $55 |
| Almatica Pharma LLC | 2 | $55 |
| Corium, LLC | 2 | $49 |
| OWP Pharmaceuticals, Inc. | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Novo Nordisk | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 1 | $39 |
| Bausch Health US, LLC | 2 | $33 |
| Livanova USA, Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Orexo US, Inc. | 1 | $18 |
| Biogen | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
Too few psychosomatic medicine providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $12,543 |
| Bupropion XlBupropion Hcl | 30 | $985 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 15 | $682 |
| Fluoxetine Hcl | 12 | $158 |
| Trazodone Hcl | 17 | $145 |
| Sertraline Hcl | 20 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $190 | $12,54312 claims |
| Almatica Pharma LLCSertraline Hcl | $55 | $12420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychosomatic medicine providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other psychosomatic medicine in Skokie
- Rukhsana IqbalHinsdale$882
- Elizabeth BernardinoBurr Ridge$121
- Arturo FogataElgin$111
- Sharon LieteauChicago$104
- Scott DavisHighland Park$34
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.